October's Editor's Choice in Gynecologic Oncology features two-year RAMP 201 results evaluating avutometinib + defactinib in recurrent LGSOC, including response durability and long-term safety.
Read the research: gynecologiconcology-online.net/article/S0090-…
Read the research: gynecologiconcology-online.net/article/S0090-…